• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Hepatocellular carcinoma in a large Canadian urban centre: stage at treatment and its potential determinants.加拿大一大型城市中心的肝细胞癌:治疗时的分期及其潜在决定因素。
Can J Gastroenterol Hepatol. 2014 Mar;28(3):150-4. doi: 10.1155/2014/561732.
2
The effectiveness of ultrasound surveillance for hepatocellular carcinoma in a Canadian centre and determinants of its success.加拿大中心对肝细胞癌进行超声监测的效果及其成功的决定因素。
Can J Gastroenterol Hepatol. 2015 Jun-Jul;29(5):267-73. doi: 10.1155/2015/563893.
3
Barcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective.巴塞罗那临床肝癌分期系统在多民族亚洲人中对肝细胞癌的分期表现优于香港肝癌分期系统:基于现实世界的视角
World J Gastroenterol. 2017 Jun 14;23(22):4054-4063. doi: 10.3748/wjg.v23.i22.4054.
4
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study.巴塞罗那临床肝癌分期和肝移植对肝细胞癌患者的生存获益:一项多中心队列研究。
Lancet Oncol. 2011 Jul;12(7):654-62. doi: 10.1016/S1470-2045(11)70144-9. Epub 2011 Jun 16.
5
Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.供体肝移植后肝细胞肝癌患者的临床结局。
World J Gastroenterol. 2013 Aug 7;19(29):4737-44. doi: 10.3748/wjg.v19.i29.4737.
6
Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia.巴塞罗那临床肝癌指南推荐范围内和范围外的肝细胞癌肝切除术:来自东亚一家大容量肝脏外科中心的结果。
J Surg Oncol. 2020 Dec;122(8):1587-1594. doi: 10.1002/jso.26183. Epub 2020 Aug 19.
7
Liver resection for HCC outside the BCLC criteria.超出巴塞罗那临床肝癌(BCLC)标准的肝细胞癌肝切除术
Langenbecks Arch Surg. 2018 Feb;403(1):37-44. doi: 10.1007/s00423-017-1640-3. Epub 2017 Dec 4.
8
Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.1998 年至 2009 年期间肝癌患者的流行病学、治疗和生存趋势:德国 HCC 登记处 1066 例病例分析。
J Clin Gastroenterol. 2014 Mar;48(3):279-89. doi: 10.1097/MCG.0b013e3182a8a793.
9
A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria.基于单个肿瘤>7cm 和多个肿瘤超出 up-to-seven 标准的改良早期和中期肝细胞癌分期。
Aliment Pharmacol Ther. 2019 Jan;49(2):202-210. doi: 10.1111/apt.15074. Epub 2018 Dec 2.
10
Assigning Treatment to HCC Patients for Transplantation: Utility of a New Decision-Making Tool.为肝癌患者分配移植治疗方案:一种新决策工具的效用
Ann Transplant. 2016 Oct 28;21:668-674. doi: 10.12659/aot.899715.

引用本文的文献

1
Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations.迈向丙型肝炎病毒消除:埃及的经验、成就和局限。
World J Gastroenterol. 2018 Oct 14;24(38):4330-4340. doi: 10.3748/wjg.v24.i38.4330.
2
The Geography of Primary Hepatic Neoplasms Treatments in Canada: Changes in Latitudes and Changes in Attitudes.加拿大原发性肝脏肿瘤治疗的地域分布:观念在转变,地域在变迁。
Can J Gastroenterol Hepatol. 2017;2017:9365657. doi: 10.1155/2017/9365657. Epub 2017 Jul 26.
3
Trends in health care utilization and costs attributable to hepatocellular carcinoma, 2002-2009: a population-based cohort study.2002 - 2009年肝细胞癌相关的医疗保健利用和费用趋势:一项基于人群的队列研究。
Curr Oncol. 2016 Jun;23(3):e196-220. doi: 10.3747/co.23.2956. Epub 2016 Jun 9.
4
Improved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study.安大略省接受推荐腹部超声监测的病毒性肝炎所致肝细胞癌患者生存率提高:一项基于人群的回顾性队列研究
PLoS One. 2015 Sep 23;10(9):e0138907. doi: 10.1371/journal.pone.0138907. eCollection 2015.
5
The effectiveness of ultrasound surveillance for hepatocellular carcinoma in a Canadian centre and determinants of its success.加拿大中心对肝细胞癌进行超声监测的效果及其成功的决定因素。
Can J Gastroenterol Hepatol. 2015 Jun-Jul;29(5):267-73. doi: 10.1155/2015/563893.

本文引用的文献

1
Report of the 18th follow-up survey of primary liver cancer in Japan.日本原发性肝癌第18次随访调查报告。
Hepatol Res. 2010 Nov;40(11):1043-1059. doi: 10.1111/j.1872-034X.2010.00731.x.
2
Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review.肝细胞癌:筛查的成本效益。系统评价。
Risk Manag Healthc Policy. 2012;5:49-54. doi: 10.2147/RMHP.S18677. Epub 2012 Jun 19.
3
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.欧洲肝脏研究学会-欧洲肿瘤内科学会临床实践指南:肝细胞癌的管理
J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.
4
Management of hepatocellular carcinoma: an update.肝细胞癌的管理:最新进展
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.
5
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.亚太肝病学会肝癌共识建议。
Hepatol Int. 2010 Mar 18;4(2):439-74. doi: 10.1007/s12072-010-9165-7.
6
Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital.澳大利亚教学医院肝癌筛查计划的效果和成本。
J Gastroenterol Hepatol. 2010 May;25(5):951-6. doi: 10.1111/j.1440-1746.2009.06203.x.
7
Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre.肝细胞癌的诊断与治疗:安大略省渥太华医院癌症中心共识会议的结果。
Curr Oncol. 2010 Apr;17(2):6-12. doi: 10.3747/co.v17i2.555.
8
Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis.肝癌监测和适当的治疗选择可改善肝硬化患者的生存。
Eur J Cancer. 2010 Mar;46(4):744-51. doi: 10.1016/j.ejca.2009.12.018. Epub 2010 Jan 8.
9
Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus.定期进行影像学监测以早期发现和改善丙型肝炎病毒感染患者的肝细胞癌预后。
J Gastroenterol. 2010;45(1):105-12. doi: 10.1007/s00535-009-0131-x. Epub 2009 Oct 29.
10
Hepatocellular carcinoma in Keio affiliated hospitals--diagnosis, treatment, and prognosis of this disease.庆应义塾大学附属医院的肝细胞癌——该疾病的诊断、治疗及预后
Keio J Med. 2009 Sep;58(3):161-75. doi: 10.2302/kjm.58.161.

加拿大一大型城市中心的肝细胞癌:治疗时的分期及其潜在决定因素。

Hepatocellular carcinoma in a large Canadian urban centre: stage at treatment and its potential determinants.

出版信息

Can J Gastroenterol Hepatol. 2014 Mar;28(3):150-4. doi: 10.1155/2014/561732.

DOI:10.1155/2014/561732
PMID:24619637
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4071879/
Abstract

OBJECTIVE

To determine whether there is a significant difference in tumour stage between patients initially found with hepatocellular carcinoma (HCC) at a tertiary hepatobiliary centre and patients referred with tumours detected elsewhere; and to determine variables associated with referral in a palliative stage.

METHODS

A retrospective review of 12,199 patients seen at a liver clinic over a 10.5-year period revealed 236 patients with HCC first detected internally (internal) and 163 who were referred with a known mass (referred). All patients were staged at the time of treatment using the Milan criteria for transplantation and Barcelona Clinic Liver Cancer (BCLC) staging system. Curative disease was defined as BCLC stages 0 and A. In the referred group, univariate and multivariate analyses were used to determine which of the following factors were significantly associated with presentation in a palliative stage: age, sex, ethnicity, cause of liver disease, presence of cirrhosis, location of residence and quintile of neighbourhood income.

RESULTS

In comparing the internal versus referred patients, significant differences were found in the proportion of patients fulfilling Milan criteria (72% versus 36%), those with curative disease (75% versus 49%) and those with very early stage tumour (BCLC stage 0, 23% versus 7%); all differences were statistically significant (P<0.001). In patients referred for treatment of HCC from an outside institution, none of the variables tested were associated with presentation in a palliative stage.

CONCLUSION

Patients with HCC referred to a liver treatment centre were more likely to be in palliative stages than those whose tumour was detected internally.

摘要

目的

确定在三级肝胆中心最初发现肝细胞癌 (HCC) 的患者与因其他地方发现肿瘤而转诊的患者之间肿瘤分期是否存在显著差异;并确定在姑息治疗阶段与转诊相关的变量。

方法

对在肝科诊所就诊的 12199 例患者进行回顾性分析,发现 236 例 HCC 患者最初在内部发现(内部),163 例患者因已知肿块转诊(转诊)。所有患者在治疗时均根据米兰标准用于移植和巴塞罗那临床肝癌 (BCLC) 分期系统进行分期。治愈性疾病定义为 BCLC 分期 0 期和 A 期。在转诊组中,使用单变量和多变量分析来确定以下哪些因素与姑息治疗阶段的表现显著相关:年龄、性别、种族、肝病病因、肝硬化存在、居住地位置和社区收入五分位数。

结果

在比较内部与转诊患者时,在符合米兰标准的患者比例(72% 对 36%)、具有治愈性疾病的患者比例(75% 对 49%)和非常早期肿瘤患者比例(BCLC 分期 0 期,23% 对 7%)方面存在显著差异;所有差异均具有统计学意义(P<0.001)。在因 HCC 从外部机构转诊接受治疗的患者中,测试的变量均与姑息治疗阶段的表现无关。

结论

与在内部发现肿瘤的患者相比,转诊到肝脏治疗中心的 HCC 患者更有可能处于姑息治疗阶段。